Skip to main content
SpringerLink
Log in

Chemotherapy for Epithelial Ovarian Cancer

  • Chapter
Gynecologic Cancer

Part of the book series: M. D. Anderson Cancer Care Series ((MDCCS,volume 5))

  • 890 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Readings

  • Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950–1955.

    Article  CAS  PubMed  Google Scholar 

  • Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002;7(suppl 5):20–28.

    CAS  PubMed  Google Scholar 

  • Bell J, Brady M, Lage J, et al. Arandomized phase III trial of three versus six cycles of carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2003;88:156.

    Google Scholar 

  • Bertelsen K, Jakobsen A, Stroyer I, et al. A prospective randomized comparison of 6 and 12 courses of cyclophosphamide, Adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 1993;49:30–36.

    Article  CAS  PubMed  Google Scholar 

  • Boruta DM, Fowler WC, Gehrig PA, et al. Weekly paclitaxel infusion as salvage therapy in ovarian cancer. Cancer Invest 2003;21:675–681.

    CAS  PubMed  Google Scholar 

  • Clarke-Pearson DL, Van Le L, Iveson T, et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol 2001;19:3967–3975.

    CAS  PubMed  Google Scholar 

  • Dizon DS, Dupont J, Anderson S, et al. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol 2003;91:584–590.

    Article  CAS  PubMed  Google Scholar 

  • Dizon DS, Hensley ML, Poynor EA, et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 2002;20:1238–1247.

    Article  CAS  PubMed  Google Scholar 

  • Donato ML, Aleman A, Champlin RE, et al. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 2004;33:1219–1224.

    Article  CAS  PubMed  Google Scholar 

  • Emons G, Weiss S, Ortmann O, et al. LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer. Eur J Endocrinol 2000;142:665–670.

    Article  CAS  PubMed  Google Scholar 

  • Gershenson DM, Mitchell M, Atkinson N. The effect of prolonged cisplatin-based chemotherapy on progression free survival in patients with optimal epithelial ovarian cancer. “Maintenance” therapy reconsidered. Gynecol Oncol 1992;47:7–13.

    Article  CAS  PubMed  Google Scholar 

  • Gershenson DM, Morris M, Burke T, et al. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte colony-stimulating factor in patients with suboptimal advanced epithelial ovarian cancer or peritoneal cancer. Cancer 1999;86:2291–2300.

    Article  CAS  PubMed  Google Scholar 

  • Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312–3322.

    CAS  PubMed  Google Scholar 

  • Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7–33.

    CAS  PubMed  Google Scholar 

  • Hakes TB, Hoskins CE, Hoskins WJ, et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992;45:284–289.

    Article  CAS  PubMed  Google Scholar 

  • Hoskins P, Eisenhauer E, Beare S, et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998;16:2233–2237.

    CAS  PubMed  Google Scholar 

  • International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomized trial. Lancet 2002;360:505–515.

    Google Scholar 

  • Jacob JN, Gershenson DM, Morris M, et al. Neoadjuvant chemotherapy and interval debulking surgery for advanced ovarian cancer. Gynecol Oncol 1991;42:146–150.

    Article  CAS  PubMed  Google Scholar 

  • Jemal A, Tiwari RC, Murray T, et al. Cancer statistics. CA Cancer J Clin 2004;54:8–29.

    PubMed  Google Scholar 

  • Kavanagh JJ, Kudelka AP, de Leon CG, et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 1996;2:837–842.

    CAS  PubMed  Google Scholar 

  • Kavanagh J, Tresukosol D, Edwards C, et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 1995;13:1584–1588.

    CAS  PubMed  Google Scholar 

  • Kaye SB, Piccart M, Aapro M, et al. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer—an updated overview. Eur J Cancer 1997;33:2167–2170.

    Article  CAS  PubMed  Google Scholar 

  • Ledermann JA. High-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) in ovarian cancer. Int J Gynecol Cancer 2001;10(suppl 1):53–56.

    Google Scholar 

  • Lund B, Hansen OP, Neijt JP, et al. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Anticancer Drugs 1995;6:61–62.

    CAS  PubMed  Google Scholar 

  • Malpica A, Deavers M, Lu K, et al. Grading ovarian serous carcinoma using a twotier system. Am J Surg Pathol 2004;28:496–504.

    PubMed  Google Scholar 

  • Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001–1007.

    CAS  PubMed  Google Scholar 

  • Markman M, Liu FY, Zilczynski S, et al. Phase III trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;13:2460–2465.

    Google Scholar 

  • McGuire WP, Blessing JA, Bookman MA, et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2000;18:1062–1067.

    CAS  PubMed  Google Scholar 

  • McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1–6.

    Article  CAS  PubMed  Google Scholar 

  • Miller DS, Blessing JA, Lentz SS, et al. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 2003;98:1664–1669.

    CAS  PubMed  Google Scholar 

  • Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000;18:106–115.

    CAS  PubMed  Google Scholar 

  • Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194–3200.

    CAS  PubMed  Google Scholar 

  • Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099–2106.

    CAS  PubMed  Google Scholar 

  • Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998;16:405–410.

    CAS  PubMed  Google Scholar 

  • Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004;351:2489–2497.

    Article  CAS  PubMed  Google Scholar 

  • Rubin SC, Hoskins WJ, Hakes TB, et al. Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors. Am J Obstet Gynecol 1988;159:1094–1098.

    CAS  PubMed  Google Scholar 

  • Spriggs D. Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecol Oncol 2004;90:S39–S44.

    Google Scholar 

  • Stebbing J, Gaya A. Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer. Cancer Treat Rev 2002;28:121–125.

    Article  CAS  PubMed  Google Scholar 

  • ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183–2193.

    PubMed  Google Scholar 

  • ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Classic Papers Curr Comments 2002;7:133–143.

    Google Scholar 

  • Topuz E, Eralp Y, Saglam S, et al. Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following frontline therapy for epithelial ovarian cancer. Consolidative intraperitoneal cisplatin in ovarian cancer. Gynecol Oncol 2004;92:147–151.

    Article  CAS  PubMed  Google Scholar 

  • Trimble EL, Adams JD, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993;11:2405–2410.

    CAS  PubMed  Google Scholar 

  • Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant Chemotherapy in Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95:105–112.

    PubMed  Google Scholar 

  • van der Burg MEL, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995;332:629–634.

    PubMed  Google Scholar 

  • Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinomas. J Natl Cancer Inst 2004;96:1682–1691.

    CAS  PubMed  Google Scholar 

  • Vergote I, De Wever I, Tjalma W, et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998;71:431–436.

    Article  CAS  PubMed  Google Scholar 

  • Williams CJ. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev 2000;(2):CD001034.

    Google Scholar 

  • Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990;322:1021–1027.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Blood and Marrow Transplantation, USA

    Michele L. Donato MD (Associate Professor)

  2. Department of Gynecologic Medical Oncology, USA

    Xipeng Wang MD (Postdoctoral Fellow) & John J. Kavanagh MD (Chair Ad Interim and Professor)

  3. Department of Gynecologic Oncology, USA

    David M. Gershenson MD (Chair and Professor)

Authors
  1. Michele L. Donato MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xipeng Wang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John J. Kavanagh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David M. Gershenson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1202, Houston, TX, 77030-4009, USA

    Patricia J. Eifel MD

  2. Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1362, Houston, TX, 77030-4009, USA

    David M. Gershenson MD

  3. Department of Gynecologic Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1364, Houston, TX, 77030-4009, USA

    John J. Kavanagh MD

  4. Department of Pathology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 85, Houston, TX, 77030-4009, USA

    Elvio G. Silva MD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Donato, M.L., Wang, X., Kavanagh, J.J., Gershenson, D.M. (2006). Chemotherapy for Epithelial Ovarian Cancer. In: Eifel, P.J., Gershenson, D.M., Kavanagh, J.J., Silva, E.G. (eds) Gynecologic Cancer. M. D. Anderson Cancer Care Series, vol 5. Springer, New York, NY. https://doi.org/10.1007/0-387-28796-5_12

Download citation

  • DOI: https://doi.org/10.1007/0-387-28796-5_12

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-28794-2

  • Online ISBN: 978-0-387-28796-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation